EUROPEAN PHARMACEUTICAL PRICING AND REIMBURSEMENT

Policies and Trends in the Five Major Markets

Despite increasingly coordinated trade activities within the European Union (EU), the five major European pharmaceutical markets (France, Germany, Italy, Spain, and the UK) retain unique approaches to setting reimbursement prices on pharmaceuticals. Country-specific systems based on differing sets of authorities, negotiation processes, and fundamental principles (including pharmacoeconomics) complicate the approval of pharmaceutical prices in these countries. Meanwhile, the ongoing evolution of health care and pharmaceutical reimbursement systems in these countries provide further challenges for a pharmaceutical company considering a European product launch.

In Europe, increasing economic pressures have led to a recent rise in efforts to curtail pharmaceutical spending by national health care authorities, despite the extensive medical advances of the past few decades. While France, Italy, and Spain tightly regulate drug prices and have historically kept them at relatively low levels, this practice has resulted in a burgeoning parallel trade to higher-priced markets such as Germany and the UK. While German and British authorities encourage this trade, they are also increasingly exploring alternative mechanisms for limiting pharmaceutical expenditures, such as mandated product substitution, the use of a "positive list" of reimbursable pharmaceuticals, and regulated price setting for generics.

Objective

This publication provides pharmaceutical executives, as well as market planning and business development teams, with greater insights on the issue of pharmaceutical pricing and reimbursement in Europe, and special in-depth coverage of key policies and authorities with critical roles. With this European Pharmaceutical Pricing and Reimbursement Report, you will obtain valuable, new information, expert opinions, and actionable insights.

Understand the Essentials of European Pharmaceutical Pricing

Gain insight into the regulatory issues that impact pharmaceutical pricing in Europe to:

• Better anticipate regulatory hurdles   
• Refine price approval timelines   
• Account for differential price windows in planning European product launches

Identify Key Pharmaceutical Pricing Authorities

Use contact information . Including post mail addresses, telephone numbers, and email addresses . For key pharmaceutical pricing authorities to:   

• Contact the appropriate pricing authorities directly   
• Reduce time wasted on tracking down names and phone numbers   
• Expedite the price approval process in target countrymarkets

About EP Publications

Enhance your perspective through EP Publications, a service of WWMR, Inc. Each report pinpoints and evaluates key trends and markets, enabling clients to identify opportunities and augment strategic decisions. In-house consultants with industry experience use qualitative and quantitative research methodologies to provide the most comprehensive and insightful business intelligence available in the life sciences industry.